CRISPR Therapeutics AG (CRSP)
60.66
+3.58
(+6.28%)
USD |
NASDAQ |
Aug 25, 14:40
CRISPR Therapeutics Total Liabilities (Quarterly) : 904.22M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 904.22M |
| March 31, 2026 | 911.26M |
| December 31, 2025 | 343.43M |
| September 30, 2025 | 329.33M |
| June 30, 2025 | 318.59M |
| March 31, 2025 | 336.94M |
| December 31, 2024 | 309.95M |
| September 30, 2024 | 316.47M |
| June 30, 2024 | 358.90M |
| March 31, 2024 | 355.08M |
| December 31, 2023 | 346.77M |
| September 30, 2023 | 359.04M |
| June 30, 2023 | 380.99M |
| March 31, 2023 | 389.47M |
| December 31, 2022 | 367.58M |
| September 30, 2022 | 399.40M |
| June 30, 2022 | 372.53M |
| March 31, 2022 | 361.26M |
| December 31, 2021 | 352.42M |
| September 30, 2021 | 308.80M |
| June 30, 2021 | 295.72M |
| Date | Value |
|---|---|
| March 31, 2021 | 152.41M |
| December 31, 2020 | 163.73M |
| September 30, 2020 | 141.72M |
| June 30, 2020 | 135.86M |
| March 31, 2020 | 121.20M |
| December 31, 2019 | 127.33M |
| September 30, 2019 | 128.71M |
| June 30, 2019 | 126.56M |
| March 31, 2019 | 118.06M |
| December 31, 2018 | 96.82M |
| September 30, 2018 | 101.59M |
| June 30, 2018 | 87.98M |
| March 31, 2018 | 84.12M |
| December 31, 2017 | 83.51M |
| September 30, 2017 | 103.36M |
| June 30, 2017 | 107.17M |
| March 31, 2017 | 107.17M |
| December 31, 2016 | 112.12M |
| September 30, 2016 | 155.62M |
| June 30, 2016 | 157.72M |
| March 31, 2016 | 152.37M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 7.175B |
| BeOne Medicines Ltd. | 3.973B |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 142.85M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.651B |
| Shareholders Equity (Quarterly) | 1.747B |
| Debt to Equity Ratio | 0.4487 |
| Current Ratio | 17.85 |
| Net Debt Paydown Yield | -2.14% |